Luminex Corp. has joined the U.S. battle against the Zika virus. The FDA gave Luminex, of Austin, Texas, emergency use authorization (EUA) for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen). The Xmap Multiflex Zika RNA assay was designed by the company's partner, Genarraytion Inc., of Rockville, Md.